188 related articles for article (PubMed ID: 21336637)
1. Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.
Heerma van Voss MR; van der Groep P; Bart J; van der Wall E; van Diest PJ
Cell Oncol (Dordr); 2011 Feb; 34(1):3-10. PubMed ID: 21336637
[TBL] [Abstract][Full Text] [Related]
2. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.
Schwartz T; Stark A; Pang J; Awuah B; Kleer CG; Quayson S; Kingman S; Aitpillah F; Abantanga F; Jiagge E; Oppong JK; Osei-Bonsu E; Martin I; Yan X; Toy K; Adjei E; Wicha M; Newman LA
Cancer; 2013 Feb; 119(3):488-94. PubMed ID: 22930220
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 regulates human mammary stem/progenitor cell fate.
Liu S; Ginestier C; Charafe-Jauffret E; Foco H; Kleer CG; Merajver SD; Dontu G; Wicha MS
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1680-5. PubMed ID: 18230721
[TBL] [Abstract][Full Text] [Related]
4. Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer.
Isfoss BL; Holmqvist B; Alm P; Olsson H
Histopathology; 2012 Mar; 60(4):617-33. PubMed ID: 22260461
[TBL] [Abstract][Full Text] [Related]
5. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas.
Madjd Z; Ramezani B; Molanae S; Asadi-Lari M
Asian Pac J Cancer Prev; 2012; 13(6):2973-8. PubMed ID: 22938492
[TBL] [Abstract][Full Text] [Related]
6. Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
Isfoss BL; Holmqvist B; Sand E; Forsell J; Jernström H; Olsson H
BMC Cancer; 2018 Feb; 18(1):230. PubMed ID: 29486751
[TBL] [Abstract][Full Text] [Related]
7. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
9. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
10. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
Ginestier C; Hur MH; Charafe-Jauffret E; Monville F; Dutcher J; Brown M; Jacquemier J; Viens P; Kleer CG; Liu S; Schott A; Hayes D; Birnbaum D; Wicha MS; Dontu G
Cell Stem Cell; 2007 Nov; 1(5):555-67. PubMed ID: 18371393
[TBL] [Abstract][Full Text] [Related]
11. Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer.
Mieog JS; de Kruijf EM; Bastiaannet E; Kuppen PJ; Sajet A; de Craen AJ; Smit VT; van de Velde CJ; Liefers GJ
BMC Cancer; 2012 Jan; 12():42. PubMed ID: 22280212
[TBL] [Abstract][Full Text] [Related]
12. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.
Zhang Y; Liss AL; Chung E; Pierce LJ; Kleer CG
Breast Cancer Res Treat; 2016 Jul; 158(1):21-28. PubMed ID: 27290698
[TBL] [Abstract][Full Text] [Related]
13. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
14. Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression.
Bednarz-Knoll N; Nastały P; Żaczek A; Stoupiec MG; Riethdorf S; Wikman H; Müller V; Skokowski J; Szade J; Sejda A; Wełnicka-Jaśkiewicz M; Pantel K
Oncotarget; 2015 Sep; 6(29):26789-803. PubMed ID: 26305673
[TBL] [Abstract][Full Text] [Related]
15. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.
Burga LN; Tung NM; Troyan SL; Bostina M; Konstantinopoulos PA; Fountzilas H; Spentzos D; Miron A; Yassin YA; Lee BT; Wulf GM
Cancer Res; 2009 Feb; 69(4):1273-8. PubMed ID: 19190334
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
17. ALDH1 as a functional marker of cancer stem and progenitor cells.
Douville J; Beaulieu R; Balicki D
Stem Cells Dev; 2009; 18(1):17-25. PubMed ID: 18573038
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
19. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
20. Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers.
Heerma van Voss MR; van der Groep P; Bart J; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2010 Sep; 123(2):611-2. PubMed ID: 20585849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
